Literature DB >> 26758536

The SPARCS: a novel assessment of contrast sensitivity and its reliability in patients with corrected refractive error.

Yi Sun1, Elif Erdem1, Andrew Lyu1, Camila Zangalli1, Sheryl S Wizov1, David Lo1, Eric E Spaeth2, Jesse Richman1, George L Spaeth1.   

Abstract

PURPOSE: To explore the reliability of the Spaeth/Richman Contrast Sensitivity (SPARCS) test and to assess the contrast sensitivity (CS) distribution among subjects with various refractive errors.
METHODS: Cross-sectional study. Ninety-three individuals (182 eyes) with varying amounts of refractive error were included in this study and divided into six groups according to their spherical equivalent. CS was evaluated using Pelli-Robson (PR) and SPARCS assessments. Each eye was tested twice with both measurements. Outcomes included the correlations of PR and SPARCS scores, the test-retest agreement of the two measurements and the limits of agreement between tests of CS measurements. The distribution of CS among the six groups was compared.
RESULTS: Pearson correlation analysis showed statistically significant correlations between SPARCS and PR scores (p<0.001). Reliability analysis showed that SPARCS had better test-retest agreement than PR, with SPARCS exhibiting a higher intraclass coefficient (ICC=0.635). Bland-Altman plots showed that the mean difference of measurements was close to 0 for both CS measurements. Among the six refractive groups, there were no significant differences in CS scores with either measurement.
CONCLUSIONS: SPARCS appears to be a reliable assessment for CS. The difference in CS among myopes, emmetropes and hyperopes wearing their habitual correction was statistically insignificant in this study. CLINICAL TRIAL NUMBER: NCT01300949, post results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Diagnostic tests/Investigation; Imaging; Visual perception

Mesh:

Year:  2016        PMID: 26758536     DOI: 10.1136/bjophthalmol-2015-307378

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  Assessment of contrast sensitivity by Spaeth Richman Contrast Sensitivity Test and Pelli Robson Chart Test in patients with varying severity of glaucoma.

Authors:  Sahil Thakur; Parul Ichhpujani; Suresh Kumar; Ravneet Kaur; Sunandan Sood
Journal:  Eye (Lond)       Date:  2018-05-14       Impact factor: 3.775

2.  The relationship between contrast sensitivity and retinal nerve fiber layer thickness in patients with glaucoma.

Authors:  Sarah Amanullah; Joseph Okudolo; Kamran Rahmatnejad; Shuai-Chun Lin; Sheryl S Wizov; Remy S Manzi Muhire; Lisa A Hark; Cindy X Zheng; Tingting Zhan; George L Spaeth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-09-05       Impact factor: 3.117

3.  Spaeth/Richman Contrast Sensitivity in Staging Glaucoma.

Authors:  Aparna Rao; Anindita Pal; Shreya Mohapatra
Journal:  Transl Vis Sci Technol       Date:  2020-12-22       Impact factor: 3.283

Review 4.  [The role of citicoline in glaucoma].

Authors:  Anselm G M Jünemann; P Grieb; R Rejdak
Journal:  Ophthalmologe       Date:  2021-03-17       Impact factor: 1.059

5.  Effects of Citicoline, Homotaurine, and Vitamin E on Contrast Sensitivity and Visual-Related Quality of Life in Patients with Primary Open-Angle Glaucoma: A Preliminary Study.

Authors:  Pier Franco Marino; Gemma Caterina Maria Rossi; Giuseppe Campagna; Decio Capobianco; Ciro Costagliola
Journal:  Molecules       Date:  2020-11-29       Impact factor: 4.411

Review 6.  Visual function tests for glaucoma practice - What is relevant?

Authors:  Aparna Rao; Debananda Padhy; Anindita Pal; Avik Kumar Roy
Journal:  Indian J Ophthalmol       Date:  2022-03       Impact factor: 2.969

7.  Precision and Normative Values of a New Computerized Chart for Contrast Sensitivity Testing.

Authors:  Giacomo Savini; Antonio Calossi; Domenico Schiano-Lomoriello; Piero Barboni
Journal:  Sci Rep       Date:  2019-11-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.